Allogeneic Hematopoietic Cell Transplantation

[1]  T. Tanimoto,et al.  Ruxolitinib for Acute Graft-versus-Host Disease. , 2020, The New England journal of medicine.

[2]  K. Strauch,et al.  Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3-Internal Tandem Duplication Mutation (SORMAIN). , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  M. Mohty,et al.  Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease. , 2020, The New England journal of medicine.

[4]  M. Sorror,et al.  Survival, Nonrelapse Mortality, and Relapse-Related Mortality After Allogeneic Hematopoietic Cell Transplantation: Comparing 2003–2007 Versus 2013–2017 Cohorts , 2020, Annals of Internal Medicine.

[5]  B. van der Holt,et al.  Post-Transplantation Cyclophosphamide after Allogeneic Hematopoietic Stem Cell Transplantation: Results of the Prospective Randomized HOVON-96 Trial in Recipients of Matched Related and Unrelated Donors. , 2019, Blood.

[6]  M. Perales,et al.  Selection of unrelated donors and cord blood units for hematopoietic cell transplantation: guidelines from the NMDP/CIBMTR , 2019, Blood.

[7]  C. Hemmelmann,et al.  Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial. , 2019, The Lancet. Haematology.

[8]  K. Götze,et al.  Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial. , 2018, The Lancet. Oncology.

[9]  G. Mufti,et al.  Reduced Relapse Incidence with FLAMSA-RIC Compared with Busulfan/Fludarabine for Acute Myelogenous Leukemia Patients in First or Second Complete Remission: A Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. , 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[10]  Michael Stadler,et al.  Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML. , 2018, Blood.

[11]  A. Ganser,et al.  Comparison of FLAMSA-based reduced intensity conditioning with treosulfan/fludarabine conditioning for patients with acute myeloid leukemia: an ALWP/EBMT analysis , 2018, Bone Marrow Transplantation.

[12]  N. Kröger,et al.  MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD. , 2018, Blood.

[13]  H. Eich,et al.  Long-term efficacy of reduced-intensity versus myeloablative conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: retrospective follow-up of an open-label, randomised phase 3 trial. , 2018, The Lancet. Haematology.

[14]  E. Leifer,et al.  Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  M. Arcila,et al.  Multicolor Flow Cytometry and Multi-Gene Next Generation Sequencing Are Complimentary and Highly Predictive for Relapse in Acute Myeloid Leukemia Following Allogeneic Hematopoietic Stem Cell Transplant , 2016 .

[16]  M. Sorror,et al.  Up-to-date tools for risk assessment before allogeneic hematopoietic cell transplantation , 2016, Bone Marrow Transplantation.

[17]  H. Einsele,et al.  Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016 , 2016, Annals of Hematology.

[18]  N. Schmitz,et al.  Allogeneic Stem Cell Transplantation Improves Survival in Patients with Acute Myeloid Leukemia Characterized by a High Allelic Ratio of Mutant FLT3-ITD. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[19]  M. Murad,et al.  Survival after mesenchymal stromal cell therapy in steroid-refractory acute graft-versus-host disease: systematic review and meta-analysis. , 2016, The Lancet. Haematology.

[20]  N. Schmitz,et al.  Hematopoietic cell transplantation in patients with intermediate and high-risk AML: results from the randomized Study Alliance Leukemia (SAL) AML 2003 trial , 2014, Leukemia.

[21]  G. Ehninger,et al.  Early intervention with allogeneic hematopoietic cell transplantation during chemotherapy-induced aplasia in patients with high-risk acute myeloid leukemia , 2013, Leukemia.

[22]  O. Landt,et al.  The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML. , 2013, Blood.

[23]  R. Schlenk,et al.  The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach , 2012, Nature Reviews Clinical Oncology.

[24]  F. Appelbaum,et al.  Comparative outcomes of donor graft CD34+ selection and immune suppressive therapy as graft-versus-host disease prophylaxis for patients with acute myeloid leukemia in complete remission undergoing HLA-matched sibling allogeneic hematopoietic cell transplantation. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  A. Gratwohl.  The EBMT risk score , 2012, Bone Marrow Transplantation.

[26]  C. Craddock,et al.  Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia , 2011, Leukemia.

[27]  M. Maris,et al.  Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  A. Krishnan,et al.  A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens. , 2010, Blood.

[29]  J. Klein,et al.  Allogeneic Hematopoietic Cell Transplantation Can Cure Some Patients with Acute Leukemia in Relapse or Primary Induction Failure: A CIBMTR Study. , 2009 .

[30]  H. Einsele,et al.  Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. , 2009, The Lancet. Oncology.

[31]  Hisashi Sakamaki,et al.  Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. , 2009, JAMA.

[32]  M. Labopin,et al.  Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  Augustin Ferrant,et al.  Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? , 2007, Blood.

[34]  W. Hiddemann,et al.  Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. , 2006, Blood.

[35]  T. Naoe,et al.  Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission , 2005, Cancer.

[36]  Bob Löwenberg,et al.  Prognostic index for adult patients with acute myeloid leukemia in first relapse. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  A. Ganser,et al.  Proteomics applied to the clinical follow-up of patients after allogeneic hematopoietic stem cell transplantation. , 2004, Blood.

[38]  T. Lion,et al.  Sequential monitoring of chimerism and detection of minimal residual disease after allogeneic blood stem cell transplantation (BSCT) using multiplex PCR amplification of short tandem repeat-markers , 2001, Leukemia.